Insider Transactions in Q1 2024 at Organogenesis Holdings Inc. (ORGO)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Patrick Bilbo Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
152,250
+15.8%
|
$152,250
$1.18 P/Share
|
|
Feb 21
2024
|
Jon L Giacomin Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+26.35%
|
-
|
|
Feb 21
2024
|
Michele Ilene Korfin Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+26.62%
|
-
|
|
Feb 21
2024
|
Patrick Bilbo Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
187,318
+22.12%
|
-
|
|
Feb 21
2024
|
Gary S. Gillheeney President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
685,131
+22.48%
|
-
|
|
Feb 21
2024
|
Lori Freedman Chief Admin. and Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
153,061
+24.52%
|
-
|
|
Feb 21
2024
|
Brian Grow Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
173,469
+24.91%
|
-
|
|
Feb 21
2024
|
David Francisco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,350
+27.21%
|
-
|
|
Feb 21
2024
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Grant, award, or other acquisition
|
Direct |
43,732
+20.46%
|
-
|
|
Feb 21
2024
|
Prathyusha Duraibabu Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+25.55%
|
-
|
|
Feb 21
2024
|
Arthur S Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+21.38%
|
-
|
|
Feb 21
2024
|
Michael Joseph Driscoll Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+26.39%
|
-
|
|
Feb 21
2024
|
Gilberto Quintero Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+26.62%
|
-
|
|
Feb 16
2024
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
719
-0.57%
|
$2,157
$3.48 P/Share
|
|
Feb 16
2024
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
791
-0.17%
|
$2,373
$3.48 P/Share
|
|
Feb 16
2024
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
804
-0.3%
|
$2,412
$3.48 P/Share
|
|
Feb 16
2024
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
646
-0.2%
|
$1,938
$3.48 P/Share
|
|
Feb 16
2024
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,788
-0.23%
|
$11,364
$3.48 P/Share
|
|
Feb 16
2024
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-0.23%
|
$2,397
$3.48 P/Share
|
|
Feb 15
2024
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
9,909
-3.65%
|
$29,727
$3.68 P/Share
|
|
Feb 15
2024
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,533
-2.96%
|
$88,599
$3.68 P/Share
|
|
Feb 15
2024
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,479
-3.89%
|
$67,437
$3.68 P/Share
|
|
Feb 15
2024
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,159
-3.69%
|
$75,477
$3.68 P/Share
|
|
Feb 15
2024
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
87,213
-2.49%
|
$261,639
$3.68 P/Share
|
|
Feb 15
2024
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,084
-2.99%
|
$66,252
$3.68 P/Share
|
|
Jan 10
2024
|
Albert Erani > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
35,944
-0.03%
|
$143,776
$4.28 P/Share
|
|
Jan 09
2024
|
Albert Erani > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
395,842
-0.33%
|
$1,583,368
$4.37 P/Share
|